NCT07065409View on ClinicalTrials.gov

Treatment of Moyamoya Disease With iPSC-derived Exosomes

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

October 31, 2026

Conditions
Moyamoya Disease
Interventions
BIOLOGICAL

iPSC-EVs

iPSC-EVs，The drug number is NouvSoma002-01. It is from iRegene Therapeutics Co., Ltd.

Trial Locations (1)

430030

RECRUITING

Tongji hospital, Wuhan

All Listed Sponsors
lead

Huaqiu Zhang

OTHER